

Application No.: 10/699,563

Docket No.: 5998-0506PUS3

Docket No.: 5998-0506PUS3
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Bradford Van Wagenen et al.

Application No.: 10/699,563

Confirmation No.: 1604

Filed: November 3, 2003

Art Unit: 1625

For: HETEROPOLYCYCLIC COMPOUNDS AND
THEIR USE AS METABOTROPIC
GLUTAMATE RECEPTOR ANTAGONISTS

Examiner: Z. N. Davis

ASSENT OF ASSIGNEES TO INVENTORSHIP CORRECTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This letter is filed as part of a petition under 37 C.F.R. § 1.48(a). The above-identified application is assigned to the following two entities:

First Assignee: NPS PHARMACEUTICALS, INC.


Address: 383 Colorow Drive
Salt Lake City, UT 84108 USA

Second Assignee: ASTRAZENECA AB

Address: Global Intellectual Property
SE-151 85 Södertälje, Sweden

A first Assignment by the original inventors to NPS Pharmaceuticals in the parent application USSN 10/076,618 was recorded at Reel 012758 / Frame 0798. Copies of two other executed assignments by newly added inventors and assigning 50% to AstraZeneca AB are also attached.

The Assignees hereby assent to the correction of inventorship described in a Petition to Add Inventors filed with a Request for Continued Examination on December 6, 2005.

I. NAMES AND SIGNATURES OF ASSIGNEES		
AstraZeneca AB	By:  Name: Bo Hasslev Title: Director IP Finance & IS	Date: 31 Jan 2006
II. NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date:

III. NAMES AND SIGNATURES OF ASSIGNEES		
NPS Pharmaceuticals, Inc.	By: _____ Name: Title:	Date:
IV. NAMES AND SIGNATURES OF WITNESSES		
Name:	Signature:	Date:
Name:	Signature:	Date: